Clinical Trials Logo

Optic Atrophy, Hereditary, Leber clinical trials

View clinical trials related to Optic Atrophy, Hereditary, Leber.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05293626 Active, not recruiting - Clinical trials for Leber Hereditary Optic Neuropathy (LHON)

Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 Mutations

Start date: May 22, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The objective of this clinical study is to evaluate the safety and efficacy of NR082 in the treatment of LHON caused by mitochondrial ND4 gene mutation. This study will enroll subjects aged ≥ 18 years old and ≤ 75 years old to receive a single unilateral intravitreal (IVT) injection of NR082 to evaluate its safety and efficacy. The clinical manifestations of all subjects are to be reduced visual acuity caused by LHON associated with ND4 mutation, with laboratory test showing G11778A mutation (a CLIA-certified laboratory) and reduced visual acuity lasted for > 6 months and < 10 years.

NCT ID: NCT03428178 Active, not recruiting - Clinical trials for Onset Between 12 to 24 Months

Efficacy Study of Gene Therapy for The Treatment of Acute LHON Onset Within Three Months

LHON
Start date: January 8, 2018
Phase: N/A
Study type: Interventional

Efficacy Study of Gene Therapy for The Treatment of Acute Leber's Hereditary Optic Neuropathy (LHON) onset within three months

NCT ID: NCT03293524 Active, not recruiting - Clinical trials for Leber Hereditary Optic Neuropathy

Efficacy & Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year

REFLECT
Start date: March 12, 2018
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to assess the safety and efficacy of GS010, a gene therapy, in improving the retina functional & structural outcomes in subjects with LHON due to the G11778A ND4 mitochondrial mutation when vision loss duration is present up to one year.

NCT ID: NCT03153293 Active, not recruiting - Clinical trials for Leber Hereditary Optic Neuropathy

A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy

Start date: December 27, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

This study is meant to evaluate the safety and efficacy of rAAV2-ND4 treatment for Leber hereditary optic neuropathy with the G11778A mutation in mitochondrial DNA.

NCT ID: NCT02161380 Active, not recruiting - Clinical trials for Leber's Hereditary Optic Neuropathy

Safety Study of an Adeno-associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy

LHON
Start date: July 14, 2014
Phase: Phase 1
Study type: Interventional

Hypotheses: The primary hypothesis being tested is that there will be no toxicity resulting in loss of vision to no light perception in injected eyes.